Tag Archive for: Novo Nordisk

Citing a JAMA study that found Ozempic could be profitably produced at under $5 per month, Senator Bernie Sanders on Wednesday called on Novo Nordisk to lower prices for the diabetes treatment and the weight-loss drug Wegovy.

Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart. The company’s therapeutic approach targets distinctive non-coding RNAs as a platform for addressing root causes of cardiac dysfunctions with an aim to achieve lasting patient impact.

Following its label expansion earlier this month, Medicare on Thursday said it will now cover the use of Novo Nordisk’s Wegovy in patients with overweight or obesity who have preexisting cardiovascular disease.

A new analysis from the Congressional Budget Office predicts that Novo Nordisk’s semaglutide will likely be subjected to Medicare’s Drug Price Negotiation Program under the Inflation Reduction Act.

Large volumes of diabetes drug Ozempic are not being exported from Germany, its health ministry said, quashing a suggestion by its drugs regulator that outbound trade in the drug, coveted for its weight-loss effect, may have to be banned.

Novo Nordisk’s investment of more than half a billion dollars is meant to expand its production capabilities in China and help it meet the global drug demand.

The foundation receives its funds from the wholly owned subsidiary Novo Holdings, through which it controls Wegovy maker Novo Nordisk as well as other companies.

The Danish drugmaker hopes to develop amycretin in its oral and injectable form simultaneously.

Novo Nordisk said early trial data for its highly anticipated experimental obesity drug amycretin showed a higher weight loss compared with its popular Wegovy treatment, sending its shares to new record highs.

Novo Nordisk expects to file for regulatory approvals of a label expansion for Ozempic in the US and EU in 2024. The detailed results from FLOW will be presented at a scientific conference in 2024.